

SINGER KAREN  
Form SC 13D/A  
January 04, 2013

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 13D/A**

**Under the Securities Exchange Act of 1934**

**(Amendment No. 4)**

HealthWarehouse.com, Inc.

(Name of Issuer)

**Common Stock**

(Title of Class of Securities)

**42227G202**

(CUSIP Number)

**Karen Singer**

**212 Vacarro Drive**

**Cresskill, NJ 07626**

**(201) 750-0415**

(Name, Address and Telephone Number  
of Person Authorized to Receive Notices  
and Communications)

**December 31, 2012**

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report this acquisition that is the subject of this Schedule 13D, and is filing this Schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box: x

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP No. 42227G202 SCHEDULE 13D/A4

**NAME OF REPORTING PERSON**

**1 I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)**

Karen Singer

**CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)**

**2**

(a)  x

(b)  ..

**SEC USE ONLY**

**3**

**SOURCE OF FUNDS (SEE INSTRUCTIONS)**

**4**

OO

**CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ..**

**5**

**CITIZENSHIP OR PLACE OF ORGANIZATION**

**6**

UNITED STATES

**NUMBER OF**

**SHARES**

**7 SOLE VOTING POWER**

**BENEFICIALLY** 1,971,660

**OWNED BY**

**EACH** **8 SHARED VOTING POWER**  
-0-

**REPORTING**

**PERSON** **9 SOLE DISPOSITIVE POWER**  
1,971,660

**WITH**

**10 SHARED DISPOSITIVE POWER**  
-0-

**AGGREGATE AMOUNT  
BENEFICIALLY OWNED BY EACH  
REPORTING PERSON**

1,971,660\*

**11** \* The shares reported herein consist of (i) 716,484 shares of common stock, (ii) 189,796 shares of Series B Preferred Stock, with each share of Series B Preferred Stock convertible into 5 shares of common stock, and (iii) convertible notes in the amount of \$578,710.41, which are convertible into shares of Series B Preferred Stock at a price of \$9.45 per share, with each share of Series B Preferred Stock convertible into 5 shares of common stock.

**12** **CHECK BOX IF THE AGGREGATE  
AMOUNT IN ROW (11) EXCLUDES  
CERTAIN SHARES (see(see  
INSTRUCTIONS) "**  
(SEE INSTRUCTIONS)

**13** **PERCENT OF CLASS REPRESENTED  
BY AMOUNT IN ROW (11)**  
15.0% <sup>1</sup>

**14** **TYPE OF REPORTING PERSON**  
IN

<sup>1</sup> The percentages reported in this Schedule 13D/A are based upon 13,106,361 outstanding shares of Common Stock (as described in Item 5 hereof).

2

CUSIP No. 42227G202

**NAME OF REPORTING  
PERSON**

**1**

**I.R.S. IDENTIFICATION NO.  
OF ABOVE PERSON  
(ENTITIES ONLY)**

Lloyd I. Miller, III

**CHECK THE APPROPRIATE  
BOX IF A MEMBER OF A  
GROUP (SEE  
INSTRUCTIONS)**

**2**

(a)  x

(b)  ..

**SEC USE ONLY**

**3**

**SOURCE OF FUNDS (SEE  
INSTRUCTIONS)  
PF-AF-OO**

**4**

**CHECK BOX IF  
DISCLOSURE OF LEGAL  
PROCEEDINGS IS  
REQUIRED PURSUANT TO  
ITEMS 2(d) OR 2(e) ..**

**5**

**6 CITIZENSHIP OR PLACE OF ORGANIZATION**  
 UNITED STATES

<b>NUMBER OF SHARES</b>	<b>7</b>	<b>SOLE VOTING POWER</b>	1,971,660
<b>BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH</b>	<b>8</b>	<b>SHARED VOTING POWER</b>	-0-
<b>WITH</b>	<b>9</b>	<b>SOLE DISPOSITIVE POWER</b>	1,971,660
	<b>10</b>	<b>SHARED DISPOSITIVE POWER</b>	-0-

**11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON**

1,971,660\*

\* The shares reported herein consist of (i) 716,484 shares of common stock, (ii) 189,796 shares of Series B Preferred Stock, with each share of Series B Preferred Stock convertible into 5 shares of common stock, and (iii) convertible notes in the amount of \$578,710.41, which are convertible into shares of Series B Preferred Stock at a price of \$9.45 per share, with each share of Series B Preferred

Stock convertible into 5 shares of  
common stock.

**12**                    **CHECK BOX IF THE  
AGGREGATE AMOUNT IN  
ROW (11) EXCLUDES  
CERTAIN SHARES (see(see  
INSTRUCTIONS) "**  
(SEE INSTRUCTIONS)

**13**                    **PERCENT OF CLASS  
REPRESENTED BY  
AMOUNT IN ROW (11)**  
15.0% <sup>2</sup>

**14**                    **TYPE OF REPORTING  
PERSON**  
                          IN

<sup>2</sup> The percentages reported in this Schedule 13D/A are based upon 13,106,361 outstanding shares of Common Stock (as described in Item 5 hereof).



SCHEDULE 13D/A4

This constitutes Amendment No. 4 (the "Amendment No. 4") to (i) the statement on Schedule 13D filed on behalf of Karen Singer ("Singer"), dated and filed November 18, 2010 (the "Original Singer Statement") and (ii) the statement on Schedule 13D filed on behalf of Lloyd I. Miller III ("Miller"), dated and filed November 18, 2010 (the "Original Miller Statement") and, together with the Original Singer Statement, the "Original Statements"), each relating to the shares ("Shares") of common stock (the "Common Stock") of HealthWarehouse.com, Inc. (the "Company" or the "Issuer"). Amendment No. 3 (the "Joint Amendment No. 3") to the Original Statements was filed on behalf of Singer, as trustee of Singer Children's Management Trust (the "Trust"), and Miller, on July 10, 2012 to report, among other things, that Singer and Miller had formed a "group" pursuant to Rule 13d-5(b)(1) of the Securities Exchange Act of 1934, as amended. Each of Singer and Miller is referred to herein as a "Reporting Person" and collectively as the "Reporting Persons." The Company's principal executive offices are located at 7107 Industrial Road, Florence, Kentucky 41042. Unless specifically amended or modified hereby, the disclosure set forth in the Original Statements, as amended, and the Joint Amendment No. 3, shall remain unchanged.

**Item 4. Purpose of the Transaction.**

Item 4 is hereby amended by adding the following to the end thereof:

This Amendment No. 4 is being filed to report that on December 31, 2012, a Letter (the "December 31 Letter") was sent to the Board of Directors of the Company on behalf of the Reporting Persons stating, among other things, that (i) all amounts owed by the Company to HWH and Milfam I under those certain 7% Senior Secured Convertible Promissory Notes issued November 8, 2010 (the "Convertible Notes") by the Company to the Reporting Persons had matured and, as a result, had become immediately due and payable as of December 31, 2012, (ii) the Company was in violation of a covenant in the Loan and Security Agreement, dated as of November 8, 2010 (the "Loan Agreement"), relating to the Convertible Notes by permitting a lien to exist on certain of the Company's assets that serve as collateral for the Convertible Notes, (iii) the Company was in violation of covenant in the Loan Agreement by borrowing an aggregate amount of \$826,000 from certain lenders in violation of the terms of the Loan Agreement and the Convertible Notes, and (iv) to the extent all amounts due and owing under the Convertible Notes are not paid by the Company to the Reporting Persons, the Reporting Persons intend to pursue all rights and remedies available to them and to take all actions necessary to enforce such rights in connection therewith.

Except as described above in this Item 4 and herein, the Reporting Persons do not currently have any specific plans or proposals that relate to or would result in any of the actions or events specified in clauses (a) through (j) of Item 4 of Schedule 13D. The Reporting Persons reserve the right to change plans and take any and all actions that the Reporting Persons may deem appropriate to maximize the value of their investments, including, among other things, purchasing or otherwise acquiring additional securities of the Company, selling or otherwise disposing of any securities of the Company beneficially owned by them, in each case in the open market or in privately negotiated transactions or

formulating other plans or proposals regarding the Company or its securities to the extent deemed advisable by the Reporting Persons in light of their general investment policies, market conditions, subsequent developments affecting the Company and the general business and future prospects of the Company. The Reporting Persons may take any other action with respect to the Company or any of the Company's debt or equity securities in any manner permitted by applicable law.

**Item 5. Interest in Securities of the Issuer**

Item 5 of the Prior Statement is hereby amended and restated in its entirety as follows:

(a) Singer, as Trustee of the Trust which is the sole member of HWH, is the beneficial owner of 1,971,660 Shares, which is equal to 15.0% of the 13,106,361 outstanding Shares. As of the date hereof, 1,971,660 of the Shares beneficially owned by Singer are owned of record by HWH.

Miller may be deemed to beneficially own 1,971,660 Shares, which is equal to 15.0% of the 13,106,361 outstanding Shares. As of the date hereof, 1,971,660 of the Shares beneficially owned by Miller are owned of record by Milfam I.

Pursuant to Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended, the 13,106,361 outstanding Shares referenced above is the sum of the following amounts: (i) 11,851,185 Shares based on the Issuer's 10-Q filed on December 31, 2012, (ii) 189,796 shares of Series B Preferred Stock, with each share of Series B Preferred Stock convertible into 5 Shares of Common Stock (including accrued and unpaid dividends through January 3, 2013), and (iii) Convertible Notes in the amount of \$578,710.41 (which includes interest through January 3, 2013), which are convertible into shares of Series B Preferred Stock at a price of \$9.45 per share, with each share of Series B Preferred Stock convertible into 5 Shares of Common Stock.

Each of the Reporting Persons, as a member of a "group" with the other Reporting Person pursuant Rule 13d-5(b)(1) of the Exchange Act, may be deemed to beneficially own the Shares owned by the other Reporting Person. The filing of this Schedule 13D shall not be deemed an admission that either Reporting Person is, for purposes of Section 13(d) of the Exchange Act, the beneficial owner of any Shares he, she or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the Shares reported herein that he, she or it does not directly own.

**(b)** Singer has sole dispositive and voting power for the Shares owned by the Trust.

Miller has sole dispositive and voting power for the Shares owned by Milfam I.

**(c)** Not applicable.

**(d)** No persons other than Singer (or HWH) and Miller (or Milfam I) have the right to receive or the power to direct the receipt of distributions or dividends from, or the proceeds from the transfer of, the reported securities.

**(e)** Not applicable.

**SIGNATURES**

After reasonable inquiry and to the best of the undersigned's knowledge and belief, the undersigned hereby certifies that the information set forth in this statement is true, complete and correct.

Dated: January 4, 2013

KAREN SINGER

By: /s/ Karen Singer

Lloyd I. Miller, III

By: /s/ Lloyd I. Miller, III